A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder …
PA Ott, R Govindan, A Naing… - Annals of …, 2018 - annalsofoncology.org
Background: Neoantigens arise from DNA mutations in cancer cells and are important
targets for T cells. Adjuvant therapy with a personal neoantigen vaccine induced T cell
responses in melanoma (mel) patients and suggested synergy with anti-PD1 mAbs (Ott et al,
Nature 2017). NEO-PV-01 is a personal neoantigen vaccine of up to 20 peptides (14-35
amino acids) designed based on bioinformatic analysis of a patient's neoantigen and HLA
profile. We report clinical and immune data of NEO-PV-01 in combination with nivolumab …
targets for T cells. Adjuvant therapy with a personal neoantigen vaccine induced T cell
responses in melanoma (mel) patients and suggested synergy with anti-PD1 mAbs (Ott et al,
Nature 2017). NEO-PV-01 is a personal neoantigen vaccine of up to 20 peptides (14-35
amino acids) designed based on bioinformatic analysis of a patient's neoantigen and HLA
profile. We report clinical and immune data of NEO-PV-01 in combination with nivolumab …